SCHEMBL5715066

SCHEMBL5715066

Cc1cccc(CCN2CCN(C(=O)Oc3ccc(CSc4nccn4C)cc3)CC2)n1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.45
POLB P06746 3/20 0.41
HDAC1 Q13547 1/20 0.40
TP53 P04637 2/20 0.38
THRB P10828 1/20 0.37
NPC1 O15118 5/20 0.37
RAB9A P51151 4/20 0.37
LMNA P02545 2/20 0.37
KCNH2 Q12809 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MEN1 O00255 1/20 0.35
HPGD P15428 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714500 0.95 SMN1; SMN2 (0.43) SMN1; SMN2POLBHDAC1NPC1RAB9A
SCHEMBL5714513 0.92 MAPT (0.38) SMN1; SMN2POLBTP53THRBNPC1
SCHEMBL5715317 0.92 SMN1; SMN2 (0.46) SMN1; SMN2POLBHDAC1NPC1RAB9A
SCHEMBL5715293 0.89 TP53 (0.49) SMN1; SMN2POLBHDAC1TP53THRB
SCHEMBL5714995 0.88 SIGMAR1 (0.42) KMT2AALDH1A1
SCHEMBL5715265 0.86 SMN1; SMN2 (0.45) SMN1; SMN2POLBHDAC1THRBNPC1
SCHEMBL5714923 0.86 KMT2A (0.40) POLBKMT2AALDH1A1KDM4E
SCHEMBL5715376 0.85 SMN1; SMN2 (0.46) SMN1; SMN2POLBHDAC1TP53THRB
SCHEMBL5716251 0.85 SMN1; SMN2 (0.47) SMN1; SMN2POLBHDAC1NPC1RAB9A
SCHEMBL5714767 0.84 SMN1; SMN2 (0.46) SMN1; SMN2POLBHDAC1TP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL SMN1; SMN2 3125/4885POLB 2674/4885HDAC1 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.